利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

76 条记录 (耗时 0.051 秒)

    Death domain containing receptor 4
    41.
    发明申请
    Death domain containing receptor 4 有权
    死亡域含受体4

    公开(公告)号：US20050112090A9

    公开(公告)日：2005-05-26

    申请号：US10648786

    申请日：2003-08-27

    申请人： Jian Ni ,  Craig Rosen ,  Reiner Gentz

    发明人： Jian Ni ,  Craig Rosen ,  Reiner Gentz

    IPC分类号： A61K38/00 ,  A61K39/395 ,  C07K14/705 ,  C07K14/715 ,  C07K16/28 ,  A61K38/19

    CPC分类号： C07K16/2878 ,  A61K38/00 ,  A61K39/39541 ,  C07K14/70578 ,  C07K14/7151 ,  C07K2319/30 ,  C12N2799/026 ,  Y02A50/412 ,  A61K2300/00

    摘要： The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.

    摘要翻译： 本发明涉及作为肿瘤坏死因子（TNF）受体家族成员的新的含有死亡域的受体-4（DR4）蛋白。 特别地，提供编码人DR4蛋白的分离的核酸分子。 还提供了DR4多肽，载体，宿主细胞和用于制备它们的重组方法。 本发明还涉及用于鉴定DR4活性的激动剂和拮抗剂的筛选方法以及使用DR4多核苷酸和多肽的方法。 本发明还涉及使用DR4特异性抗体（其可以是DR4活性的激动剂和/或拮抗剂）的减少或增加的细胞凋亡相关疾病的治疗。

    Pancreas-derived plasminogen activator inhibitor
    43.
    发明申请
    Pancreas-derived plasminogen activator inhibitor 审中-公开
    胰腺来源的纤溶酶原激活物抑制剂

    公开(公告)号：US20060045878A1

    公开(公告)日：2006-03-02

    申请号：US11048774

    申请日：2005-02-03

    申请人： Jian Ni ,  Reiner Gentz ,  Steven Ruben ,  Y. Shi

    发明人： Jian Ni ,  Reiner Gentz ,  Steven Ruben ,  Y. Shi

    IPC分类号： C07H21/04 ,  A61K39/395 ,  C07K16/44 ,  C12N5/06

    CPC分类号： C07K14/81 ,  A61K38/00 ,  A61K48/00 ,  C07K14/8132 ,  C07K2319/00 ,  Y02A50/463

    摘要： The present invention relates to a novel member of the plasminogen activator inhibitor protein family. In particular, isolated nucleic acid molecules are provided encoding the pancreas-derived plasminogen activator inhibitor protein. Pancreas-derived plasminogen activator inhibitor polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to methods for treating physiologic and pathologic disease conditions and diagnostic methods for detecting pathologic disorders.

    摘要翻译： 本发明涉及纤溶酶原激活物抑制剂蛋白家族的新成员。 特别地，提供编码胰腺衍生的纤溶酶原激活物抑制蛋白的分离的核酸分子。 还提供了胰腺来源的纤溶酶原激活物抑制剂多肽，载体，宿主细胞和用于制备它们的重组方法。 本发明还涉及用于治疗生理和病理疾病状况的方法以及用于检测病理学疾病的诊断方法。

    T1 Receptor-Like Ligand II and Uses Thereof
    47.
    发明申请
    T1 Receptor-Like Ligand II and Uses Thereof 审中-公开
    T1受体样配体II及其用途

    公开(公告)号：US20070280903A1

    公开(公告)日：2007-12-06

    申请号：US11554432

    申请日：2006-10-30

    申请人： Jian Ni ,  Reiner Gentz ,  Steven Ruben

    发明人： Jian Ni ,  Reiner Gentz ,  Steven Ruben

    IPC分类号： A61K38/19 ,  A61K38/17 ,  C12Q1/68 ,  A61K38/18

    CPC分类号： G01N33/564 ,  A61K38/1709 ,  A61K38/20 ,  A61K45/06 ,  A61K48/00 ,  C07K14/54 ,  C12N2799/026 ,  G01N33/57407 ,  G01N33/57426 ,  G01N33/6893 ,  G01N33/6896 ,  G01N2800/24 ,  G01N2800/2821 ,  G01N2800/368

    摘要： The present invention relates to a novel T1 Receptor (T1R)-like ligand II protein. In particular, isolated nucleic acid molecules are provided encoding the T1R-like ligand II protein. T1R-like ligand II polypeptides are also provided, as are recombinant vectors and host cells for expressing the same. This invention further relates to pharmaceutical compositions and formulations comprising T1R-like ligand II. Also provided are methods of using T1R-like ligand II polynucleotides, polypeptides, antibodies or agonists/antagonists for therapeutic and diagnostic purposes. Diagnostic kits are further provided.

    摘要翻译： 本发明涉及一种新颖的T1受体（T1R）样配体II蛋白。 特别地，提供编码T1R样配体II蛋白质的分离的核酸分子。 还提供了T1R样配体II多肽，重组载体和用于表达它们的宿主细胞也是如此。 本发明还涉及包含T1R样配体II的药物组合物和制剂。 还提供了用于治疗和诊断目的的T1R样配体II多核苷酸，多肽，抗体或激动剂/拮抗剂的方法。 还提供诊断试剂盒。

    Novel Metalloproteinases
    48.
    发明申请
    Novel Metalloproteinases 审中-公开
    新型金属蛋白酶

    公开(公告)号：US20070238130A1

    公开(公告)日：2007-10-11

    申请号：US11627246

    申请日：2007-01-25

    申请人： Jian Ni ,  Steven Ruben ,  Laurie Brewer ,  Reiner Gentz ,  Craig Rosen

    发明人： Jian Ni ,  Steven Ruben ,  Laurie Brewer ,  Reiner Gentz ,  Craig Rosen

    IPC分类号： C12P1/04 ,  C07H21/04 ,  C07K14/00 ,  C07K16/18 ,  G01N33/53 ,  C12N15/00 ,  C12N5/06

    CPC分类号： C12N9/6489 ,  A61K38/00 ,  C07K14/47 ,  C07K14/705 ,  C07K14/70535 ,  C12N9/00 ,  C12N9/6475 ,  C12N9/6491 ,  C12N2799/026

    摘要： The present invention relates to novel metalloproteinase- like proteins. In particular, isolated nucleic acid molecules are provided encoding the human TACE-like and matrilysin-like proteins. TACE-like and matrilysin-like polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TACE-like and matrilysin-like activity. Also provided are diagnostic methods for detecting cancer and therapeutic methods for cancer and other disorders characterized by an over or under production of these metalloproteinases.

    摘要翻译： 本发明涉及新型金属蛋白酶样蛋白质。 特别地，提供了分离的核酸分子，其编码人类TACE样和基质溶素样蛋白。 TACE样和基质溶素样多肽也可以作为载体，宿主细胞和用于制备它们的重组方法提供。 本发明进一步涉及用于鉴定TACE样和基质溶素样活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测癌症的诊断方法和癌症的治疗方法以及特征在于这些金属蛋白酶过度或过量生产的其它病症。

    Leukocyte regulatory factors 1 and 2
    49.
    发明申请
    Leukocyte regulatory factors 1 and 2 审中-公开
    白细胞调节因子1和2

    公开(公告)号：US20060063924A1

    公开(公告)日：2006-03-23

    申请号：US11272833

    申请日：2005-11-15

    申请人： Jian Ni ,  Jing-Shan Hu ,  Steven Ruben ,  Reiner Gentz

    发明人： Jian Ni ,  Jing-Shan Hu ,  Steven Ruben ,  Reiner Gentz

    IPC分类号： C07K14/475 ,  C07H21/02 ,  C12P21/06

    CPC分类号： C07K14/4702

    摘要： The present invention relates to novel LRF-1 and LRF-2 proteins which are related to the CRISP family and a protein called “Neutrophil Inhibitory Factor (NIF)” isolated from the canine hookworm (Ancylostoma caninum) that potently inhibits CD11/CD18-dependent neutrophil function. In particular, isolated nucleic acid molecules are provided encoding the human LRF-1 and LRF-2 proteins. LRF-1 and LRF-2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of LRF-1 or LRF-2 activity. Also provided are diagnostic methods for detecting immune system or other LRF-1- or LRF-2-related disorders and therapeutic methods for treating such disorders.

    摘要翻译： 本发明涉及与CRISP家族相关的新型LRF-1和LRF-2蛋白质，以及从犬钩虫（Ancylostoma caninum）中分离的称为“中性嗜中性粒细胞抑制因子（NIF）”的蛋白质，其有效抑制CD11 / CD18依赖性 中性粒细胞功能。 特别地，提供编码人LRF-1和LRF-2蛋白的分离的核酸分子。 还提供了LRF-1和LRF-2多肽，载体，宿主细胞以及用于制备它们的重组方法也是如此。 本发明还涉及用于鉴定LRF-1或LRF-2活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测免疫系统或其他LRF-1或LRF-2相关疾病的诊断方法以及用于治疗这种疾病的治疗方法。